Evidence-based approach for managing hypertension in type 2 diabetes

Figures & data

Figure 1 Algorithm for treatment of hypertension in inividuals with diabetes. Maximize dose before starting the next drug.

First line = ACEi or ARB (equivalence seen in DETAIL⁷³ ONTARGET⁷⁵ and VALIANT⁷⁶).

• Both reduce microalbuminuria and rate of nephropathy independently of their antihypertensive effect.

• ACEi preferred over ARB (indirect evidence for cardiovascular outcomes; SCOPE,⁷⁰ VALUE⁷¹ and TRANSCEND⁷²).

• Recommend against concomitant use of ARB with ACEi (ONTARGET⁷⁵ and VALIANT⁷⁶).

Second line = CCB or diuretic

• Dihydropyridine CCB favored over diuretic (ACCOMPLISH⁸² and GUARD⁸³) or in the presence of electrolyte anomalies.

• Diuretic preferred in heart failure or edematous conditions.

• Loop diuretic recommended if GFR ≤ 30 mL/min due to marked state of fluid overload.

• If needed, CCB and diuretic can be combined.

Third line = β-blocker, primarily due to side effect profile. However, it is indicated in all patients with established CAD and MI.

Fourth line = Aldosterone antagonist (ASCOT-BPLA⁸⁶).

Fifth line = Renin inhibitor or α-blocker, not enough comparative data from clinical trials for clear recommendation.

Peripheral α-blocker, due to orthostatic hypotension and results of ALLHAT.⁷⁸ It could be used earlier in patients with symptomatic BPH.

^arenal artery stenosis, hyperaldosteronism, Cushing’s syndrome or pheochromocytoma.

Abbreviations: BP, blood pressure; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CAD, coronary artery disease; MI, myocardial infarction; HTN, hypertension; GFR, glomerular filtration rate; BPH, benign prostate hyperplasia.

BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696

 PubMed Web of Science ®Google Scholar

YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520

 PubMed Web of Science ®Google Scholar

PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160

 PubMed Web of Science ®Google Scholar

LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861

 PubMed Web of Science ®Google Scholar

JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952

 PubMed Web of Science ®Google Scholar

YusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085

 PubMed Web of Science ®Google Scholar

JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124

 PubMed Web of Science ®Google Scholar

BakrisGLTotoRDMcCulloughPARochaRPurkayasthaDDavisPEffects of different ACE inhibitor combinations on albuminuria: results of the GUARD studyKidney Int200873111303130918354383

 PubMed Web of Science ®Google Scholar

ChapmanNDobsonJWilsonSEffect of spironolactone on blood pressure in subjects with resistant hypertensionHypertension200749483984517309946

 PubMed Web of Science ®Google Scholar

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763

 PubMed Web of Science ®Google Scholar